Headquartered in Durham, NC·Fiscal year ends December·NYSE MKT: PTHS·pelthos.com
About Pelthos Therapeutics
Pelthos Therapeutics Inc. (NYSE American: PTHS) is a commercial-stage biopharmaceutical company building a portfolio of differentiated products for cutaneous infectious and skin diseases.
- **Zelsuvmi (berdazimer) topical gel, 10.3%:** its lead marketed product and main revenue source. It is a prescription therapy approved for at-home use by patients, parents and caregivers to treat molluscum contagiosum.
- **Xepi (ozenoxacin) Cream, 1%:** an FDA-approved topical treatment for impetigo, with launch targeted for the first quarter of 2027.
- **Xeglyze (abametapir):** an FDA-approved topical treatment for head lice, with launch targeted for the third quarter of 2027.
- **Nitricil:** a proprietary technical and manufacturing platform.
- **Other revenue:** modest license and collaboration revenues.
The company markets to dermatology, pediatric dermatology and pediatric prescribers. Zelsuvmi has commercial formulary coverage of 127 million lives and broad Medicaid coverage.
In October 2026 Pelthos agreed to merge with Castle Creek Biosciences, a late-stage developer of redosable fibroblast-based cell and gene therapies. Castle Creek's lead candidate D-Fi targets dystrophic epidermolysis bullosa. The combined company would span marketed, launch-stage and late-stage assets focused on serious diseases affecting the skin.
Pelthos is financed partly through a senior secured term loan facility with Horizon Technology Finance and convertible notes. Updated
Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest trading weeks the stock market has seen in a long time. Despite crushing analysts’…
Pelthos Therapeutics Inc. (NYSE American: PTHS) is a commercial-stage biopharmaceutical company building a portfolio of differentiated products for cutaneous infectious and skin diseases. - **Zelsuvmi (berdazimer) topical gel, 10.3%:** its lead marketed product and main revenue source.
What is the PTHS stock price target?
The Wall Street consensus 12-month price target for PTHS is $41.43.